Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer

Overview

Journal Eur Urol Focus

Specialty Urology

Date 2022 Mar 23

PMID 35317973

Authors

Bram De Laere

Alessio Crippa

Andrea Discacciati

Berit Larsson

Jan Oldenburg

Ashkan Mortezavi

Piet Ost

Martin Eklund

Johan Lindberg

Henrik Gronberg

Affiliations

Soon will be listed here.

Abstract

ProBio is an outcome-adaptive, multiarm, multiple-assignment randomised, biomarker-driven platform trial in men with metastatic castration-resistant prostate cancer. Here we describe the amended clinical protocol, focusing on expansion of the trial to include patients with de novo metastatic hormone-sensitive prostate cancer.

Citing Articles

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S Nat Med. 2024; 30(11):3291-3302.

PMID: 39164518 PMC: 11564108. DOI: 10.1038/s41591-024-03204-2.

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.

Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R JCO Precis Oncol. 2024; 8:e2300654.

PMID: 38547422 PMC: 10994438. DOI: 10.1200/PO.23.00654.

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Fonseca N, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha A Nat Commun. 2024; 15(1):1828.

PMID: 38418825 PMC: 10902374. DOI: 10.1038/s41467-024-45475-w.

Cell-Free DNA Genomic Profiling and Its Clinical Implementation in Advanced Prostate Cancer.

Hench I, Roma L, Conticelli F, Bubendorf L, Calgua B, Le Magnen C Cancers (Basel). 2024; 16(1).

PMID: 38201475 PMC: 10778564. DOI: 10.3390/cancers16010045.

and Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer.

Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, Ustmert S Eur Urol Open Sci. 2023; 53:63-66.

PMID: 37292496 PMC: 10244905. DOI: 10.1016/j.euros.2023.05.008.